Safe Step Act
- Bill Number
- S. 2903
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2026-03-19: Committee on Health, Education, Labor, and Pensions. Hearings held.
- Last Updated
- 2026-06-16T15:01:22Z
AI-Generated Summary
Purpose
The Safe Step Act (S. 2903) aims to improve access to prescription medications by requiring group health plans and related health insurance coverage to establish a standardized process for requesting and granting exceptions to "step therapy" protocols. Step therapy is a cost-control practice where insurers require patients to try cheaper or preferred drugs before covering a more expensive one prescribed by their doctor. The legislation seeks to ensure timely exceptions when step therapy could harm a patient's health or treatment.
Key Provisions
- Exceptions Process Requirement: Group health plans and insurers must create a clear, fast, and transparent system for patients or their doctors (prescribers) to request exceptions to step therapy rules. If approved, the requested drug must be covered at the plan's standard cost-sharing rates (like copays) from the start of the plan year.
- Criteria for Approving Exceptions: Exceptions must be granted if any of these apply:
- Previous treatments (or similar ones) were ineffective, based on the doctor's judgment, clinical guidelines, or patient records.
- Delaying the preferred drug could cause severe or irreversible harm, disease worsening, or ineffective results due to the patient's unique health factors.
- Required treatments are contraindicated (medically unsafe) or likely to cause harm, supported by clinical evidence.
- Required treatments hinder the patient's ability to work or perform daily activities.
- The patient is stable on the requested drug and previously had it covered by another health plan.
- Other cases as decided by the Secretary of Labor.
- Process Standards:
- Allows submission of requests via a standard form (paper or electronic), with minimal required documentation focused only on proving the criteria.
- Permits representatives (like advocates) to submit on behalf of patients.
- Information about the process must be included in plan documents and websites, including forms and contact details.
- Timelines for Decisions:
- Standard requests: Response within 72 hours, either approving or requesting more info; final decision within another 72 hours if info is needed.
- Urgent cases (e.g., risks to life, health, function, or severe pain): Expedited review within 24 hours, with the same for any additional info requests.
- Duration of Approval: If granted, coverage for the drug lasts at least one year.
- Reporting Requirements:
- Plans and insurers must report annually to the Secretary of Labor on exception requests, approvals/denials, appeals, reasons for denials, request sources (patients vs. doctors), medical conditions involved, and pharmacy benefit managers (PBMs, third-party firms that manage drug benefits).
- Contracts with PBMs or administrators cannot block access to this data.
- The Secretary must summarize and analyze reports for Congress and make them public annually, starting three years after enactment.
Significant Changes to Existing Law
- Amends the Employee Retirement Income Security Act of 1974 (ERISA), which governs private employer-sponsored health plans, by adding a new section (713A) mandating an exceptions process for step therapy—previously, such processes were optional or varied by plan.
- Applies broadly to any step therapy policy, even if not explicitly labeled as such.
- Introduces federal oversight through required regulations (issued by the Secretary of Labor within six months of enactment) and mandatory reporting, which did not exist before.
- Effective for plan years starting at least six months after enactment.
Potential Impacts
- On Citizens/Patients: Could reduce treatment delays, improve health outcomes, and lower risks of harm from ineffective or unsafe alternative drugs, especially for chronic conditions like cancer, mental health issues, or autoimmune diseases.
- On Government Agencies: The Department of Labor gains responsibility for issuing regulations, collecting reports, and analyzing data for Congress, potentially increasing administrative workload but enabling better monitoring of health plan practices.
- On Health Plans and Insurers: May raise operational costs due to processing requests and expedited reviews, possibly leading to higher premiums; however, it standardizes practices to reduce disputes.
- On International Relations: No direct impact, as this is a domestic health policy focused on U.S. employer plans.
Main Stakeholders Affected
- Patients and Beneficiaries: Primary beneficiaries, gaining easier access to doctor-preferred medications.
- Prescribing Health Care Providers: Empowered to request exceptions with their clinical rationale, by specialty (e.g., oncologists, psychiatrists).
- Group Health Plans and Insurers: Must implement and comply with the process, including reporting.
- Pharmacy Benefit Managers (PBMs): Affected by data-sharing requirements and potential shifts in drug utilization patterns.
- Secretary of Labor and Congress: Oversee implementation, regulations, and receive annual reports for policy evaluation.
Notable Legal, Constitutional, or Political Implications
- Legal: Strengthens patient protections under ERISA by mandating evidence-based exceptions, potentially reducing lawsuits over denied coverage; clarifies that minimal documentation is required to avoid burdensome barriers, aligning with broader Affordable Care Act principles of accessible care.
- Constitutional: No apparent challenges; it regulates private health plans under Congress's commerce power without infringing on free speech or due process.
- Political: Bipartisan support (introduced by 20 senators from both parties) highlights consensus on patient-centered reforms to balance cost controls with health needs; could influence future drug pricing and utilization management debates, promoting transparency in an industry often criticized for opaque practices.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (46)
Sen. Hassan, Margaret Wood [D-NH], Sen. Marshall, Roger [R-KS], Sen. Rosen, Jacky [D-NV], Sen. Padilla, Alex [D-CA], Sen. Hickenlooper, John W. [D-CO], Sen. Merkley, Jeff [D-OR], Sen. Sullivan, Dan [R-AK], Sen. Warnock, Raphael G. [D-GA], Sen. Hyde-Smith, Cindy [R-MS], Sen. Cortez Masto, Catherine [D-NV], Sen. Moran, Jerry [R-KS], Sen. Cramer, Kevin [R-ND], Sen. Kaine, Tim [D-VA], Sen. Budd, Ted [R-NC], Sen. Shaheen, Jeanne [D-NH], Sen. Booker, Cory A. [D-NJ], Sen. Wyden, Ron [D-OR], Sen. Coons, Christopher A. [D-DE], Sen. Blumenthal, Richard [D-CT], Sen. Boozman, John [R-AR], Sen. Gillibrand, Kirsten E. [D-NY], Sen. Tillis, Thomas [R-NC], Sen. Heinrich, Martin [D-NM], Sen. Klobuchar, Amy [D-MN], Sen. Van Hollen, Chris [D-MD], Sen. Schiff, Adam B. [D-CA], Sen. Kelly, Mark [D-AZ], Sen. Fischer, Deb [R-NE], Sen. Peters, Gary C. [D-MI], Sen. Duckworth, Tammy [D-IL], Sen. Ossoff, Jon [D-GA], Sen. Smith, Tina [D-MN], Sen. Collins, Susan M. [R-ME], Sen. Gallego, Ruben [D-AZ], Sen. Warner, Mark R. [D-VA], Sen. Welch, Peter [D-VT], Sen. Whitehouse, Sheldon [D-RI], Sen. Murray, Patty [D-WA], Sen. Hirono, Mazie K. [D-HI], Sen. Kim, Andy [D-NJ], Sen. Cantwell, Maria [D-WA], Sen. Capito, Shelley Moore [R-WV], Sen. Justice, James C. [R-WV], Sen. Husted, Jon [R-OH], Sen. Murphy, Christopher [D-CT], Sen. Slotkin, Elissa [D-MI]
Recent Actions
- 2026-03-19: Committee on Health, Education, Labor, and Pensions. Hearings held.
- 2025-09-18: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- 2025-09-18: Introduced in Senate
Bill Versions
- Safe Step Act — issued 2025-09-18 — PDF (13 pages)